Reply: Cangrelor or Abciximab as First Choice in Cardiogenic Shock.

Authors	Muthiah Vaduganathan, Arman Qamar, Hisham A Badreldin, David P Faxon, Deepak L Bhatt
Journal	JACC. Cardiovascular interventions (JACC Cardiovasc Interv) Vol. 10 Issue 23 Pg. 2468-2469 (12 11 2017) ISSN: 1876-7605 [Electronic] United States
PMID	29217013 (Publication Type: Letter, Comment)
Chemical References	Immunoglobulin Fab Fragments Adenosine Monophosphate cangrelor Abciximab
Topics	Abciximab Adenosine Monophosphate (analogs & derivatives) Humans Immunoglobulin Fab Fragments Shock, Cardiogenic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!